Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor
F Guida, L Luongo, S Boccella, M E Giordano, R Romano, G Bellini, I Manzo, A Furiano, A Rizzo, R Imperatore, F A Iannotti, E D'Aniello, F Piscitelli, F Sca Rossi, L Cristino, V Di Marzo, V de Novellis, S Maione, F Guida, L Luongo, S Boccella, M E Giordano, R Romano, G Bellini, I Manzo, A Furiano, A Rizzo, R Imperatore, F A Iannotti, E D'Aniello, F Piscitelli, F Sca Rossi, L Cristino, V Di Marzo, V de Novellis, S Maione
Abstract
The endogenous fatty acid amide palmitoylethanolamide (PEA) has been shown to exert anti-inflammatory actions mainly through inhibition of the release of pro-inflammatory molecules from mast cells, monocytes and macrophages. Indirect activation of the endocannabinoid (eCB) system is among the several mechanisms of action that have been proposed to underlie the different effects of PEA in vivo. In this study, we used cultured rat microglia and human macrophages to evaluate whether PEA affects eCB signaling. PEA was found to increase CB2 mRNA and protein expression through peroxisome proliferator-activated receptor-α (PPAR-α) activation. This novel gene regulation mechanism was demonstrated through: (i) pharmacological PPAR-α manipulation, (ii) PPAR-α mRNA silencing, (iii) chromatin immunoprecipitation. Moreover, exposure to PEA induced morphological changes associated with a reactive microglial phenotype, including increased phagocytosis and migratory activity. Our findings suggest indirect regulation of microglial CB2R expression as a new possible mechanism underlying the effects of PEA. PEA can be explored as a useful tool for preventing/treating the symptoms associated with neuroinflammation in CNS disorders.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
- Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A. Physiology of microglia. Physiol. Rev. 2011;91:461–553. doi: 10.1152/physrev.00011.2010.
- McMahon SB, Malcangio M. Current challenges in glia-pain biology. Neuron. 2009;64(1):46–54. doi: 10.1016/j.neuron.2009.09.033.
- Franco R, Fernàndez-Suàrezs D. Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 2015;131:65–86. doi: 10.1016/j.pneurobio.2015.05.003.
- Sierra A, Tremblay ME, Wake H. Never-resting microglia: physiological roles in the healthy brain and pathological implications. Front. Cell. Neurosci. 2014;8:240. doi: 10.3389/fncel.2014.00240.
- von Bernhardi R, von Bernhardi Eugenín L, Eugenín. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. 2015;7:124.
- Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58(9):1017–1030. doi: 10.1002/glia.20983.
- Luongo L, et al. 1-(2′,4′-dichlorophenyl)−6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol. Dis. 2010;37:177–185. doi: 10.1016/j.nbd.2009.09.021.
- Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA. Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain. 2009;28:5–25.
- Ehrhart J, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Neuroinflammation. 2005;12(2):29. doi: 10.1186/1742-2094-2-29.
- Facci L, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 1995;92:3376–3380. doi: 10.1073/pnas.92.8.3376.
- Scarampella F, Abramo F, Noli C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet. Dermatol. 2001;12(1):29–39. doi: 10.1046/j.1365-3164.2001.00214.x.
- Skaper SD, Facci L, Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol. 2013;48(2):340–452. doi: 10.1007/s12035-013-8487-6.
- Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacol. Res. 2014;86:32–41. doi: 10.1016/j.phrs.2014.05.006.
- Koch M, et al. Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α. Neurotox Res. 2011;19(2):330–40. doi: 10.1007/s12640-010-9166-2.
- Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139:541–550. doi: 10.1016/j.pain.2008.06.003.
- Di Cesare Mannelli L, et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013;2013:328797.
- Luongo L, et al. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets. 2013;12:45–54. doi: 10.2174/1871527311312010009.
- Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006;8:298–306. doi: 10.1208/aapsj080234.
- Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nat. 1998;394:277–281. doi: 10.1038/28393.
- Calignano A, La Rana G, Loubet-Lescoulié P, Piomelli D. A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Prog. Brain. Res. 2000;129:471–482. doi: 10.1016/S0079-6123(00)29034-1.
- LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life. Sci. 2005;77:1685–1698. doi: 10.1016/j.lfs.2005.05.012.
- Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog. Lipid. Res. 2016;62:107–28. doi: 10.1016/j.plipres.2016.02.002.
- Cabral GA, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 2005;78(6):1192–1197. doi: 10.1189/jlb.0405216.
- Hains B, Waxman S. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J. Neurol. Sci. 2006;26:4308–4317.
- Chandra V, et al. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent. Nature. 2008;456(7220):350–6. doi: 10.1038/nature07413.
- Liu QR, et al. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms,differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav. 2009;8(5):519–30. doi: 10.1111/j.1601-183X.2009.00498.x.
- Farquhar-Smith W-P, Rice AS. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology. 2003;99:1391–1401. doi: 10.1097/00000542-200312000-00024.
- Showalter V, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 1996;278(3):989–999.
- Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J. 2007;173(1):21–30. doi: 10.1016/j.tvjl.2005.10.003.
- Racz I, et al. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J. Neurosci. 2008;28(46):12125–12135-a. doi: 10.1523/JNEUROSCI.3400-08.2008.
- Pasquini S, et al. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists. J. Med. Chem. 2012;55(11):5391–402. doi: 10.1021/jm3003334.
- Mugnaini C, et al. Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. Chem. Med. Chem. 2012;7(5):920–934. doi: 10.1002/cmdc.201100573.
- Luongo L, et al. 5′-Chloro-5′-deoxy-(±)-ENBA, a potent and selective adenosine A(1) receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor or cardiovascular functions. Molecules. 2012;17:13712–26. doi: 10.3390/molecules171213712.
- Guida F, et al. Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection. Mol. Pain. 2012;8:60. doi: 10.1186/1744-8069-8-60.
- Guida F, et al. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Mol. Brain. 2015;8:47-a. doi: 10.1186/s13041-015-0139-5.
- Rinaldi B, et al. Effect of Prolonged Moderate Exercise on the Changes of Nonneuronal Cells in Early Myocardial Infarction. Neural Plast. 2015;2015:265967. doi: 10.1155/2015/265967.
- Spaziano, G. et al. Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS. Biomed. Res. 980983 (2015).
- Romero-Sandovalm EA, Horvathm RJ, De Leom JA. Neuroimmune interactions and pain: focus on glial-modulating targets. Curr. Opin. Investig. Drugs. 2008;9(7):726–734.
- Milliganm E, Watkins L. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 2009;10(1):23–36. doi: 10.1038/nrn2533.
- Lin YC, et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat. Commun. 2014;5:4767. doi: 10.1038/ncomms5767.
- Loria F, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 2008;28:633–41. doi: 10.1111/j.1460-9568.2008.06377.x.
- Ribes S, et al. Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. Infect. Immun. 2010;78(2):865–71. doi: 10.1128/IAI.01110-09.
- Nau R, Ribes S, Djukic M, Eiffert H. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Front. Cell. Neurosci. 2014;8:138. doi: 10.3389/fncel.2014.00138.
- Redlich S, Ribes S, Schutze S, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections. J. Neuroinflammation. 2014;11:108. doi: 10.1186/1742-2094-11-108.
- Masek K, Perlík F, Klíma J, Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur. J. Clin. Pharmacol. 1974;7:415–9. doi: 10.1007/BF00560353.
- Redlich S, Ribes S, Scutze S, Czesnik D, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells. J. Neuroimmunol. 2012;244(1–2):32–4. doi: 10.1016/j.jneuroim.2011.12.013.
- Singhrao, S. K., Harding, A., Poole, S., Kesavalu, L. & Crean, S. Porphyromonas gingivalis Periodontal Infection and Its Putative Links with Alzheimer’s Disease. Mediators Infiamm. 137357 (2015).
- Petrosino, S. & Di Marzo, V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 13580 (2016).
- Kahlich R, et al. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J. Hyg. Epidemiol. Microbiol. Immunol. 1979;23:11–24.
- Inoue K. Microglial activation by purines and pyrimidines. Glia. 2002;40:156–163. doi: 10.1002/glia.10150.
- Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. BR. J. Pharmacol. 2008;153(2):299–308. doi: 10.1038/sj.bjp.0707523.
- Thelen M. Dancing to the tune of chemokines. Nat. Immunol. 2001;2(2):129–134. doi: 10.1038/84224.
- Fung S, Cherry AE, Xu C, Stella N. Alkylindole-sensitive receptors modulate microglial cell migration and proliferation. Glia. 2015;63:1797–1808. doi: 10.1002/glia.22845.
- Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci. 2003;23(21):7767–75.
- Walter L, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003;23(4):1398–405.
- Sacerdote P, et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J. Neuroimmunol. 2005;159(1–2):97–105. doi: 10.1016/j.jneuroim.2004.10.003.
- Gonsiorek W, et al. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 2000;57(5):1045–50.
- Sugiura T, et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem. 2000;275(1):605–12. doi: 10.1074/jbc.275.1.605.
- Martin-Moreno AM, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Mol. Pharmacol. 2011;79:964–973. doi: 10.1124/mol.111.071290.
- Di Marzo V, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 2001;358:249–255. doi: 10.1042/bj3580249.
- Clark A, Wodarski R, Guida F, Sasso O, Malcangio M. Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor. Glia. 2010;58(14):1710–1726. doi: 10.1002/glia.21042.
- Luongo L, et al. The A1 adenosine receptor as a new player in microglia physiology. Glia. 2014;62:122–132. doi: 10.1002/glia.22592.
- Iannotti FA, Barrese V, Formisano L, Miceli F, Taglialatela M. Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated Kv7.4 potassium channels. Mol. Biol. Cell. 2013;24:274–84. doi: 10.1091/mbc.E11-12-1044.
- Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, Hoareau L, Monteleone P, Roche R, Izzo AA, Di Marzo V. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol. 2007;152(5):676–90. doi: 10.1038/sj.bjp.0707424.
- Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, Berge K, Tandy S, Cohn JS, Griinari M, Banni S, Di Marzo V. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab. 2011;8(1):51. doi: 10.1186/1743-7075-8-51.
Source: PubMed